Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Cash: 2022-2025

Historic Change in Cash for Stoke Therapeutics (STOK) over the last 4 years, with Sep 2025 value amounting to -$18.2 million.

  • Stoke Therapeutics' Change in Cash rose 58.23% to -$18.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$66.5 million, marking a year-over-year decrease of 66.34%. This contributed to the annual value of -$63.2 million for FY2024, which is 181.19% down from last year.
  • As of Q3 2025, Stoke Therapeutics' Change in Cash stood at -$18.2 million, which was up 89.53% from -$173.3 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Change in Cash high stood at $146.8 million for Q1 2025, and its period low was -$173.3 million during Q2 2025.
  • Over the past 3 years, Stoke Therapeutics' median Change in Cash value was -$2.1 million (recorded in 2023), while the average stood at -$2.7 million.
  • As far as peak fluctuations go, Stoke Therapeutics' Change in Cash slumped by 1,986.41% in 2024, and later soared by 1,241.69% in 2025.
  • Quarterly analysis of 4 years shows Stoke Therapeutics' Change in Cash stood at $160,000 in 2022, then spiked by 815.62% to $1.5 million in 2023, then plummeted by 1,588.46% to -$21.8 million in 2024, then soared by 58.23% to -$18.2 million in 2025.
  • Its Change in Cash was -$18.2 million in Q3 2025, compared to -$173.3 million in Q2 2025 and $146.8 million in Q1 2025.